Cat. No.: DAB-0012344
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human |
Applications | WB, IP |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala268 of human NMNAT1 protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | NMNAT1 |
UniProt No. | Q9HAN9 |
Gene ID | 64802 |
Gene Description | Nicotinamide mononucleotide adenylyl transferases catalyze the reversible reaction of ATP with NaMN or NMN to produce NaAD or NAD. NAD is an essential cofactor or substrates for many enzymes like PARP1 and Sirt1 that regulate diverse cellular processes including oxidative reactions and transcription. NMNATs maintain NAD levels for internal homeostasis. NMNAT1 is localized to the nucleus and loss-of-function mutant in mice causes embryonic lethality. In humans, several different NMNAT1 mutations are associated with Leber congenital amaurosis, the most common cause of inherited childhood blindness. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.